Revolution Medicines: Strong Data, Big Market (Rating Upgrade)

Impact · against what's priced in

RVMD is a strong buy following practice-changing Phase 3 data for daraxonrasib in metastatic PDAC, which significantly improves survival rates and opens a multi-billion dollar market. The company's substantial liquidity further reduces financing risk during its regulatory push.

RVMD+0.90

No priced-in read yet

In context

The 60% reduction in risk of death and doubling of median overall survival in metastatic PDAC provide a clear path to a multi-billion dollar market. This clinical success is bolstered by $4B in liquidity to fund regulatory submissions.

Read from the article alone

• biotech
• RVMD
• analyst upgrade
• clinical trials
• drug development
• pancreatic cancer
• pharmaceuticals
• phase 3

Search tags